KalVista reports Q2 net loss $19.7M; advances HAE oral candidates KVD900 and KVD824

KalVista Pharmaceuticals, Inc.

2023-Q2 EPS reported -$1.46

Net loss of $19.7M ($0.80 per share) for quarter ended Oct 31, 2021 vs $10.4M ($0.58) year ago.
Cash, equivalents and marketable securities $209.8M as of Oct 31, 2021; funded into early 2024.
Preparing to initiate Phase 3 trial for KVD900 (on-demand HAE) in Q1 2022; FDA confirmed trial design.
Phase 2 KOMPLETE trial for KVD824 (prophylactic HAE) enrolling patients; regulatory approvals in 12 of 13 countries.
R&D expenses increased to $17.5M from $9.1M due to preclinical, Phase 2 and Phase 3 preparation costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.